Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035.


Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
05 2020
Historique:
received: 05 11 2019
revised: 16 01 2020
accepted: 17 01 2020
pubmed: 1 2 2020
medline: 4 11 2020
entrez: 1 2 2020
Statut: ppublish

Résumé

The incidence of gastric cancer continues to decrease globally, approaching levels that in some populations could define it as a rare disease. To explore this on a wider scale, we predict its future burden in 34 countries with long-standing population-based data. Data on gastric cancer incidence by year of diagnosis, sex and age were extracted for 92 cancer registries in 34 countries included in Overall gastric cancer incidence rates are predicted to continue falling in the future in the majority of countries, including high-incidence countries such as Japan (ASR 36 in 2010 vs ASR 30 in 2035) but also low-incidence countries such as Australia (ASR 5.1 in 2010 vs ASR 4.6 in 2035). A total of 16 countries are predicted to fall below the rare disease threshold (defined as 6 per 100 000 person-years) by 2035, while the number of newly diagnosed cases remains high and is predicted to continue growing. In contrast, incidence increases were seen in younger age groups (below age 50 years) in both low-incidence and high-incidence populations. While gastric cancer is predicted to become a rare disease in a growing number of countries, incidence levels remain high in some regions, and increasing risks have been observed in younger generations. The predicted growing number of new cases highlights that gastric cancer remains a major challenge to public health on a global scale.

Identifiants

pubmed: 32001553
pii: gutjnl-2019-320234
doi: 10.1136/gutjnl-2019-320234
pmc: PMC8520492
mid: NIHMS1742642
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

823-829

Subventions

Organisme : Intramural NIH HHS
ID : ZIA CP000185
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Lancet Gastroenterol Hepatol. 2020 Jan;5(1):42-54
pubmed: 31648970
Eur J Cancer Prev. 2002 Jun;11 Suppl 1:S1-96
pubmed: 12442806
Gastroenterology. 2017 May;152(6):1319-1328.e7
pubmed: 28147224
Medicine (Baltimore). 2015 Feb;94(8):e533
pubmed: 25715251
Gut. 2016 Jan;65(1):9-18
pubmed: 25986943
Swiss Med Wkly. 2015 Sep 16;145:w14188
pubmed: 26376322
BMJ. 2014 May 20;348:g3174
pubmed: 24846275
Dig Dis Sci. 2014 Aug;59(8):1698-709
pubmed: 24563236
Gastrointest Endosc. 2018 Sep;88(3):475-485.e2
pubmed: 29800546
BMC Gastroenterol. 2011 Apr 14;11:37
pubmed: 21489301
Stat Med. 2003 Sep 15;22(17):2751-66
pubmed: 12939784
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):700-13
pubmed: 24618998
Eur J Cancer Prev. 2018 Mar;27(2):124-133
pubmed: 27560662
Cancer Res Treat. 2011 Jun;43(2):83-8
pubmed: 21811423
Cancer Res Treat. 2018 Apr;50(2):303-316
pubmed: 29566481
Helicobacter. 2013 Oct;18(5):325-37
pubmed: 23566268
Gastroenterol Jpn. 1977;12(6):427-34
pubmed: 608564
BMJ Open. 2017 Aug 11;7(8):e016999
pubmed: 28801429
Cancer Res Treat. 2019 Apr;51(2):417-430
pubmed: 30913865
J Natl Cancer Inst. 2018 Jun 1;110(6):608-615
pubmed: 29361173
Am J Gastroenterol. 2010 May;105(5):1007-13; quiz 1006, 1014
pubmed: 20087334
Gut. 2015 Dec;64(12):1881-8
pubmed: 25748648
Eur J Cancer. 2011 Nov;47(17):2493-511
pubmed: 22033323
Nature. 2011 Aug 24;476(7361):393-4
pubmed: 21866137
Aliment Pharmacol Ther. 2011 Apr;33(8):922-9
pubmed: 21366634
Gut. 2011 Dec;60(12):1644-9
pubmed: 21613644
Nat Rev Cancer. 2006 Jan;6(1):63-74
pubmed: 16372017
Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(7):251-8
pubmed: 25169671
Helicobacter. 2012 Jun;17(3):232-7
pubmed: 22515362
Jpn J Clin Oncol. 2018 Jul 1;48(7):673-683
pubmed: 29889263
Br J Cancer. 2011 Nov 22;105(11):1795-803
pubmed: 22033277
Salud Publica Mex. 2016 Apr;58(2):104-17
pubmed: 27557369
Gastroenterology. 2017 Aug;153(2):420-429
pubmed: 28456631
Epidemiol Rev. 1986;8:1-27
pubmed: 3533579
Lancet Oncol. 2019 Mar;20(3):394-407
pubmed: 30795950
Proc Am Thorac Soc. 2012 May;9(2):69-71
pubmed: 22550247
Int J Cancer. 2015 Jan 15;136(2):487-90
pubmed: 24889903
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Lancet. 2017 Dec 16;390(10113):2627-2642
pubmed: 29029897
Helicobacter. 2010 Dec;15(6):486-90
pubmed: 21073603

Auteurs

Melina Arnold (M)

Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France arnoldm@iarc.fr.

Jin Young Park (JY)

Prevention and Implementation Group, Early Detection and Prevention Section, International Agency for Research on Cancer, Lyon, France.

M Constanza Camargo (MC)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.

Nuno Lunet (N)

Departamento Ciências da Saúde Pública e Forenses, e Educação Médica, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.

David Forman (D)

Section of Epidemiology and Biostatistics, University of Leeds Faculty of Medicine and Health, Leeds, UK.

Isabelle Soerjomataram (I)

Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH